Table 4.
Adjusted and unadjusted logistic regression after propensity score matching.
| Outcome a | No anticoagulation | Anticoagulation | Unadjusted | Adjusted * | ||
|---|---|---|---|---|---|---|
| N = 202 (50%) c | N = 202 (50%) c | OR (95% CI) b | p-value | OR (95% CI) b | p-value | |
| TICI 2b-3 | 161 (83%) | 167 (85%) | 1.14 (0.66–1.99) | 0.63 | 1.20 (0.69–2.08) | 0.52 |
| TICI 2c-3 | 109 (56%) | 111 (57%) | 1.01 (0.67–1.50) | 0.98 | 1.02 (0.68–1.53) | 0.93 |
| FPE | 57 (32%) | 66 (34%) | 1.10 (0.71–1.70) | 0.66 | 1.14 (0.73–1.80) | 0.56 |
| 90-day mRS 0–1 | 67 (33%) | 61 (30%) | 0.87 (0.57–1.33) | 0.52 | 1.05 (0.61–1.81) | 0.86 |
| 90-day mRS 0–2 | 93 (46%) | 96 (48%) | 1.06 (0.72–1.57) | 0.76 | 1.24 (0.79–1.96) | 0.35 |
| 90-day mortality | 38 (19%) | 54 (27%) | 1.57 (0.99–2.53) | 0.059 | 1.56 (0.95–2.59) | 0.082 |
| ICH (Any type) | 80 (40%) | 69 (34%) | 0.79 (0.53–1.19) | 0.26 | 0.77 (0.51–1.17) | 0.22 |
| ICH (By type) | ||||||
| HI1 | 34 (17%) | 25 (13%) | 0.70 (0.40–1.22) | 0.21 | 0.74 (0.42–1.29) | 0.28 |
| HI2 | 7 (3·5%) | 4 (2·0%) | 0.57 (0.15–1.90) | 0.37 | 0.56 (0.16–1.99) | 0.37 |
| PH1 | 8 (4·0%) | 7 (3·5%) | 0.88 (0.30–2.48) | 0.8 | 0.85 (0.30–2.41) | 0.76 |
| PH2 | 6 (3·0%) | 5 (2·5%) | 0.83 (0.24–2.81) | 0.77 | 0.89 (0.26–3.05) | 0.85 |
| SAH | 23 (12%) | 25 (13%) | 1.11 (0.60–2.03) | 0.74 | 1.06 (0.57–1.98) | 0.84 |
| Embolization in new territories | 9 (4·6%) | 8 (4·0%) | 0.87 (0.32–2.34) | 0.79 | 0.90 (0.34–2.39) | 0.83 |
| Perforation | 8 (4·1%) | 7 (3·5%) | 0.86 (0.30–2.45) | 0.78 | 0.83 (0.29–2.38) | 0.72 |
a
ICH: intracranial hemorrhage; TICI: thrombolysis in cerebral infarction; FPE: first-pass effect; HI1: hemorrhagic infarction type 1; HI2: hemorrhagic infarction type 2; PH1: parenchymal hemorrhage type 1; PH2: parenchymal hemorrhage type 2; SAH: subarachnoid hemorrhage.
b
OR: odds ratio; CI: confidence interval.
c
n (%); Median (IQR).
*
All estimates were adjusted for Sex, Age, High blood pressure, High cholesterol, Diabetes, Smoking, mRS before stroke, Baseline NIHSS, ASPECTS, Occlusion Site and onset to puncture time.